[6-K] Anghami Inc. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Renalytix plc (RNLX) filed Post-Effective Amendment No. 1 to its Form S-8 (Reg. No. 333-274732). The amendment terminates the effectiveness of the original registration statement and dere­gisters all ordinary shares (£0.0025 par value) that remain unissued under two employee programs: (1) the 2020 Employee Share Purchase Plan and (2) the 2020 Equity Incentive Plan. No new securities will be offered pursuant to these plans under this registration after the filing becomes effective, which occurs automatically upon submission under Rule 464.

The company confirms its status as a non-accelerated filer, smaller reporting company, and emerging growth company. The document is signed by CEO James McCullough in London on 25 July 2025, with no additional signatures required under Rule 478.

Positive

• Deregisters unissued shares, eliminating a source of potential future shareholder dilution.

Negative

• Reduces share-based compensation flexibility by cancelling registration of plan shares.

Insights

Financial Analyst

TL;DR – Housekeeping amendment that removes unused equity from registration; negligible operational impact.

This S-8 POS simply withdraws unissued shares tied to Renalytix’s 2020 ESPP and Equity Incentive Plan. The move halts the ability to issue those particular shares, modestly reducing potential future dilution but also limiting equity-based compensation capacity. There are no financial metrics, capital raises, or strategic signals in the filing; therefore, the market impact is expected to be neutral and purely administrative.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File Number: 001-41263

Anghami Inc.

(Exact name of registrant as specified in its charter)

16th Floor, Al-Khatem Tower, WeWork Hub71
Abu Dhabi Global Market Square, Al Maryah Island, Abu Dhabi, United Arab Emirates

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

Convertible Note Transaction

On July 25, 2025, Anghami Inc. (the “Company”) announced the sale of a senior unsecured convertible note in the amount of $23,000,000 (the “Third Note”) pursuant to the previously reported Convertible Note Purchase Agreement (the “Note Purchase Agreement”), dated December 16, 2024 (the “Initial Funding Date”), to OSN Streaming Limited, a Cayman Islands exempted company (“OSN”). The Company previously issued a senior unsecured convertible note in the amount of $12,000,000 (the “Initial Note”) and a senior unsecured convertible note in the amount of $20,000,000 (the “Second Note”) to OSN, each pursuant to the Note Purchase Agreement. OSN has purchased the full principal amount of senior unsecured convertible note under the Note Purchase Agreement and no additional notes may be issued under the Note Purchase Agreement following the issuance of the Third Note to OSN.

The Third Note will mature on December 16, 2027 (the “Maturity Date”). Interest will accrue on the outstanding principal amount of the Third Note at a rate of 11.0% per annum, payable in kind (the “PIK Interest”) by adding the accrued PIK Interest to the outstanding principal amount of the Third Note on a monthly basis.

OSN may, at its sole discretion, elect to convert any portion of the outstanding principal amount of the Third Note and the accrued and unpaid PIK Interest thereon into ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), of the Company at a per share conversion price equal to (i) $2.50, if such conversion occurs before the first anniversary of the Initial Funding Date, (ii) $2.75, if such conversion occurs on or after the first anniversary and before the second anniversary of the Initial Funding Date, or (iii) $3.00, if such conversion occurs on or after the second anniversary of the Initial Funding Date. Notwithstanding the foregoing, OSN may not convert any PIK Interest into Ordinary Shares without providing written notice to the Company of its intention to do so, which shall not be effective until the 61st day after such notice is delivered to the Company. OSN may waive this requirement by providing written notice to the Company, which shall not be effective until the 61st day after such notice is delivered to the Company. The outstanding principal amount of the Third Note and the accrued and unpaid PIK Interest thereon will be automatically converted into Ordinary Shares at a per share conversion price equal to $3.00 on the Maturity Date (subject to adjustment pursuant to the Third Note).

The Third Note includes customary covenants, subject to specified exceptions. Such covenants and exceptions include that the Company is prohibited from incurring additional debt without the consent of OSN, other than in connection with working capital and receivable financing up to $20.0 million. The Third Note includes customary events of default, the occurrence of which may result in the acceleration of the maturity of the Third Note.

The Ordinary Shares issuable upon conversion of the Third Note constitute “Registrable Securities” pursuant to, and are entitled to the benefits of, the registration rights agreement, dated April 1, 2024, by and between the Company and OSN, which is attached hereto as Exhibit 99.3.

The Company intends to use the net proceeds from the offering of the Third Note for working capital, growth, and general corporate purposes.

The foregoing descriptions of the Note Purchase Agreement and the Third Note are summaries of the material terms of such agreements, do not purport to be complete and are qualified in their entirety by reference to the Note Purchase Agreement and the Third Note, which are attached hereto as Exhibits 99.1 and 99.2, respectively.

1

EXHIBIT INDEX

Exhibit		Description
99.1*		Convertible Note Purchase Agreement, by and between the Company and OSN Streaming Limited, dated as of December 16, 2024 (incorporated by reference to Exhibit 99.2 to the Company’s the Form 6-K filed with the SEC on December 16, 2024).
99.2*#		Senior Unsecured Convertible Note, issued by the Company to OSN Streaming Limited, dated as of July 25, 2025
99.3		Registration Rights Agreement, dated April 1, 2024, by and between OSN Streaming Limited and Anghami Inc. (incorporated by reference to Exhibit 99.3 to the Company’s Form 6-K filed with the SEC on April 3, 2024).

* Certain of the exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of such schedules and exhibits, or any section thereof, to the SEC upon request.

# Certain information contained in this exhibit has been omitted pursuant to Item 601(b)(10) because such information (i) is not material and (ii) is the type of information that the Company both customarily and actually treats as private and confidential.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

	ANGHAMI INC.
Date: July 25, 2025	By:	/s/ Elias Habib
	Name:	Elias Habib
	Title:	Chief Executive Officer

3

FAQ

What did Renalytix plc file on July 25 2025?

The company filed Post-Effective Amendment No. 1 to Form S-8 to deregister unissued shares under its 2020 ESPP and Equity Incentive Plan.

How many shares are being deregistered by RNLX?

The exact number is not specified; the amendment removes all remaining unissued ordinary shares registered under the two 2020 plans.

Will Renalytix still issue shares under the 2020 plans?

No. By terminating the registration statement, no additional shares can be issued under those plans via this filing.

Does this filing affect Renalytix’s filer status?

The company remains a non-accelerated filer, smaller reporting company, and emerging growth company, as indicated in the amendment.

Who signed the Post-Effective Amendment for Renalytix?

James McCullough, Chief Executive Officer and Director, signed the document in London.